

**TOWNSEND and TOWNSEND KHOURIE and CREW**

Steuart Street Tower  
One Market Plaza  
San Francisco, CA 94103  
(415) 543-9600



**PATENT APPLICATION  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D. C. 20231**

Sir:

Transmitted herewith for filing is the  
 patent application of  
 design patent application of  
 continuation-in-part patent application of

**Inventor:** David J. LOCKHART and Mark S. CHEE

**For:** SEQUENCING BY HYBRIDIZATION ON HIGH DENSITY PROBE ARRAYS: ENZYMATIC  
DISCRIMINATION ENHANCEMENT

Enclosed are:

7 sheet(s) of  formal  informal drawing(s).  
 An assignment of the invention to \_\_\_\_\_.  
 A  signed  unsigned Declaration & Power of Attorney.  
 A  signed  unsigned Declaration.  
 A Power of Attorney.  
 A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27.  
 A certified copy of a \_\_\_\_\_ application.  
 Information Disclosure Statement under 37 CFR 1.97.

**In view of the Unsigned Declaration as filed with this application and pursuant to 37 CFR §1.53(d),  
Applicant requests deferral of the filing fee until submission of the Missing Parts of Application.**

**DO NOT CHARGE THE FILING FEE AT THIS TIME.**

Telephone:  
(415) 543-9600  
APPNO/FEETRN 12/92

C:\TEMP\37274

Atty. Docket No. 16528X-86

"Express Mail" Label No. TB175057212


Date of Deposit October 21, 1994

I hereby certify that this is being deposited with the  
United States Postal Service "Express Mail Post Office  
to Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the Commissioner  
of Patents and Trademarks, Washington, D. C. 20231

By \_\_\_\_\_

  
Dana Kane

Eugenia Garrett-Wackowski  
Reg. No.: 37,330  
Attorneys for Applicant



**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7. Other: \_\_\_\_\_

**Applicant must provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**Please return a copy of this notice with your response.**